Anthera Pharmaceuticals, Inc. (ANTH) stock gained today 87.24% on 23.9M shares in volume. We profiled ANTH as a potential bounce candidate right after the company’s report of the mixed results for its Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus. Today Anthera Pharmaceuticals came out with the positive clinical data from the […]
Anthera Pharmaceuticals (ANTH) shares plunged around 70% after company’s report of the mixed results for its Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus. Paul F. Truex, Anthera’s President and Chief Executive Officer, commented: [quote style=”1″]The extensive data in the target severe population from our Phase 2 clinical program supports the initiation […]
